BridgeBio Pharma, Inc. Common Stock (BBIO)

Price$65.36

Value ScoreF

Growth ScoreA

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-13.39%

Price vs S&P 500 (4W)-8.33%

VGM Score54.33

Market Capitalization$12.98B

All Metrics

Book Value / Share (Quarterly)$0.47

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)86.30%

Cash Flow / Share (Quarterly)$-2.31

Price vs S&P 500 (YTD)-24.31%

Gross Margin (TTM)95.13%

Net Profit Margin (TTM)-124.41%

EPS (TTM)$-3.75

10-Day Avg Trading Volume2.59M

EPS Excl Extra (TTM)$-3.75

Revenue Growth (5Y)127.44%

EPS (Annual)$-3.79

ROI (Annual)-83.58%

Gross Margin (Annual)95.82%

Net Profit Margin (5Y Avg)-1745.26%

Cash / Share (Quarterly)$4.80

Revenue Growth QoQ (YoY)66.78%

ROA (Last FY)-77.45%

Revenue Growth TTM (YoY)355.17%

EBITD / Share (TTM)$-2.70

Operating Margin (TTM)-90.52%

Cash Flow / Share (Annual)$-2.34

P/B Ratio224.14x

P/B Ratio (Quarterly)150.71x

Net Income / Employee (Annual)$-869,200

EV / Revenue (TTM)26.63x

Net Interest Coverage (TTM)-2.17x

ROA (TTM)-65.81%

EPS Incl Extra (Annual)$-3.79

Current Ratio (Annual)2.77x

Quick Ratio (Quarterly)1.40x

3-Month Avg Trading Volume2.66M

52-Week Price Return98.56%

Revenue / Employee (TTM)$695,400

Tangible BV / Share (Quarterly)$-7.09

P/S Ratio (Annual)25.85x

Asset Turnover (Annual)0.54x

52-Week High$84.94

Operating Margin (5Y Avg)-1664.55%

EPS Excl Extra (Annual)$-3.79

CapEx CAGR (5Y)4.99%

26-Week Price Return2.54%

Quick Ratio (Annual)2.53x

13-Week Price Return-2.00%

Total Debt / Equity (Annual)8.27x

Current Ratio (Quarterly)1.52x

Enterprise Value$15.44B

Revenue / Share Growth (5Y)106.45%

Asset Turnover (TTM)0.53x

Revenue / Employee (Annual)$602,000

Pretax Margin (Annual)-145.89%

Cash / Share (Annual)$3.02

3-Month Return Std Dev48.10%

Gross Margin (5Y Avg)91.77%

Net Income / Employee (TTM)$-865,200

ROE (Last FY)-774.99%

Net Interest Coverage (Annual)-2.00x

EPS Basic Excl Extra (Annual)$-3.79

Receivables Turnover (TTM)3.62x

Total Debt / Equity (Quarterly)8.27x

EPS Incl Extra (TTM)$-3.75

ROI (TTM)-65.34%

P/S Ratio (TTM)22.38x

Pretax Margin (5Y Avg)-1775.49%

Revenue / Share (Annual)$2.62

Tangible BV / Share (Annual)$-8.52

Price vs S&P 500 (52W)70.36%

Year-to-Date Return-13.37%

5-Day Price Return-4.14%

EPS Normalized (Annual)$-3.79

ROA (5Y Avg)-77.25%

Net Profit Margin (Annual)-144.39%

Month-to-Date Return-6.82%

Cash Flow / Share (TTM)$-3.94

EBITD / Share (Annual)$-2.81

Operating Margin (Annual)-108.46%

LT Debt / Equity (Annual)8.22x

ROI (5Y Avg)-78.45%

LT Debt / Equity (Quarterly)8.22x

EPS Basic Excl Extra (TTM)$-3.75

P/B Ratio (Annual)150.71x

Inventory Turnover (TTM)1.53x

Pretax Margin (TTM)-125.78%

Book Value / Share (Annual)$0.47

Price vs S&P 500 (13W)-11.74%

Beta0.96x

Revenue / Share (TTM)$2.98

ROE (TTM)-206.74%

52-Week Low$31.77

vGradeF

gGradeA

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.84est. -0.69

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.25

4.28

4.27

4.21

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	C	$65.36
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
ABTAbbott Laboratories	C	C	D	$87.78
PFEPfizer Inc.	B	C	C	$25.63
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

BridgeBio Pharma develops treatments for genetic diseases through a late-stage pipeline of four programs targeting Mendelian disorders, oncology, and gene therapy. Its lead candidate, Attruby (acoramidis), is an orally administered small molecule designed to stabilize transthyretin for the treatment of transthyretin amyloid cardiomyopathy.